Part D program has also been shown to increase long-term medication adherence for cardiovascular risk factor control. 12 However, little is known about whether Part D enrollment is associated with improved clinical outcomes post AMI.
To address this critical knowledge gap, we linked records from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines (ACTION Registry-GWTG) with US Medicare data. Our objectives were to (1) describe overall prevalence of Medicare Part D enrollment in patients hospitalized with AMI, as well as time trends and hospital variation in enrollment rates; (2) compare baseline characteristics and in-hospital management among Medicare Part D enrollees versus nonenrollees; and (3) compare 30-day and 1-year post-AMI outcomes (all-cause mortality, all-cause readmissions, and major adverse cardiac events) associated with Part D enrollment versus nonenrollment at hospital discharge. We hypothesized that Part D enrollment would be associated with more favorable 30-day and 1-year outcomes after AMI hospitalization.
Methods

Data Source
The National Cardiovascular Data Registry ACTION Registry-GWTG is a national quality improvement initiative started in 2007 that collects data for consecutive patients presenting with AMI with or without ST-segment elevation to >500 participating hospitals across the United States. 13 Detailed clinical data are retrospectively abstracted from the medical record and include patient demographics; details of presentation (mode of arrival and presenting signs and symptoms); previous medical history and home medications; in-hospital procedures and therapies; clinical events before discharge; discharge status; and medications prescribed at discharge (https:// www.ncdr.com/webncdr/action/home/datacollection). Because patient information was collected without unique patient identifiers in ACTION Registry-GWTG data, we used 5 indirect identifiers in combination (date of birth, sex, hospital identifier, date of admission, and date of discharge) to link patients age ≥65 years in this registry to their Medicare claims data; the data linkage methodology has been previously described. 14 This data linkage was supported by a Centers for Education and Research on Therapeutics grant (U19HS021092) from the Agency for Healthcare Research and Quality. The Duke University Medical Center Institutional Review Board granted a waiver of the informed consent and authorization for this study, and all analyses were conducted by the Duke Clinical Research Institute.
Study Population
Successful linkage of the ACTION Registry-GWTG and Medicare data yielded an initial population of 79 671 patients with AMI from 504 US hospitals between January 2, 2007, and December 31, 2010 ( Figure 1 ). We excluded patients who (1) died during the index hospitalization; (2) were discharged to hospice, another acute care hospital, an intermediate care facility, or skilled nursing facility; (3) left against medical advice; (4) did not have 1 full year of Medicare Parts A and B enrollment before the index AMI hospitalization (data used to ascertain noncardiovascular comorbid conditions that are not captured in ACTION Registry-GWTG); and (5) had subsequent AMI presentations (only their index AMI hospitalization was included). The final study population for this analysis included 59 149 Medicare patients with AMI treated at 502 US hospitals ( Figure 1 ).
From the overall study population, we identified Part D enrollees as those patients who were enrolled in Part D at the time of discharge for the index AMI hospitalization. Enrollees could have been enrolled in Part D before the AMI hospitalization, as long as they were still enrolled in Part D at the time of hospital discharge according to Medicare records. Patients nonenrolled in Part D at the time of hospital discharge were considered nonenrollees. The proportion of patients who enrolled in a Part D program after hospital discharge was low (5%), and therefore these patients were also considered nonenrollees at discharge for the purpose of this analysis.
Study Outcomes
Outcomes of interest were all-cause mortality, all-cause readmission, and major adverse cardiovascular events (MACE) defined as the composite of death, readmission for myocardial infarction, or readmission for stroke. These outcomes were ascertained at both 30 days (short term) and 1 year (long term). Mortality was ascertained from the Medicare denominator file. Readmissions for myocardial infarction and stroke were defined using the primary diagnosis code for all subsequent hospitalizations in the Medicare claims file (410.x1 for myocardial infarction and 433.x1, 434.x1, 997.02, 436, 437.1, 437.9, 430, 431, 432.x for stroke). All outcomes assessments started at time of discharge from the index AMI hospitalization.
Statistical Analysis
The proportion of patients enrolled in Part D among discharged patients with AMI in each month was plotted from January 2007 to December 2010, and a Cochran-Armitage test was performed to assess P value for trend. A histogram was used to plot the variation in the proportion of patients enrolled in Part D among discharged patients with AMI across US hospitals. For the 2 comparison groups (enrolled versus nonenrolled in Part D at AMI hospital discharge), baseline patient and hospital characteristics, inpatient medications and procedures, and discharge medications were reported as percentages and compared with Pearson χ 2 tests (for nominal categorical variables) and Wilcoxon rank-sum tests (for ordinal categorical variables). Continuous variables were reported as medians (with 25th and 75th percentiles) and compared with Wilcoxon rank-sum tests.
We used Kaplan-Meier methods to estimate the risks of death and MACE among Part D enrolled versus nonenrolled patients after
WHAT IS KNOWN
• Medicare Part D is an outpatient prescription drug benefit available to Medicare beneficiaries to help offset the cost of prescription medications. • Limited data are available on the relationship between enrollment in Medicare Part D and adherence to evidence-based medications and outcomes after acute myocardial infarction.
WHAT THE STUDY ADDS
• Only half of eligible Medicare-insured patients with acute myocardial infarction are enrolled in Part D by hospital discharge. • Among Part D enrollees, adherence rates to key secondary prevention medications (statins, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and P2Y 12 antagonists) at 1 year after acute myocardial infarction hospitalization are low, ranging from 55% to 64%. • Adjusted 30-d and 1-y outcomes post acute myocardial infarction are similar between Medicare beneficiaries enrolled versus not enrolled in Part D; additional research is needed to determine which aspects of prescription drug plans (such as Medicare Part D) influence adherence to evidence-based medications and long-term outcomes.
hospital discharge. To assess readmission risk, we reported cumulative incidence rates to account for death as a competing risk. We used inverse probability weighted methods to study the association of Part D enrollment with each outcome. 15 First, we created a propensity score model with Part D enrollment as the outcome, conditioning on the following covariates: age, sex, race, body mass index, 5 indicators of socioeconomic status derived from patients' zip codes, and US census data (percent patients age ≥25 years with ≥ 4 years of college, percent patients age ≥25 years with a high school diploma, percent white collar workers, median estimated household income, and median home value), as previously described 16 ; additional insurance besides Medicare and type of additional insurance (private, Medicaid, military, or other); number of hospitalizations in the previous 12 months; transfer-in status; ST-segment elevation on presenting ECG; cardiogenic shock; signs of heart failure; systolic blood pressure; heart rate; history of hypertension; diabetes mellitus; peripheral arterial disease; current or recent smoker; previous myocardial infarction; previous percutaneous coronary intervention; previous coronary artery bypass graft surgery; previous heart failure; previous stroke; dialysis; Charlson comorbidity index; preadmission medications (aspirin, P2Y 12 inhibitor, β-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and statin); baseline creatinine and troponin (ratio over institutional upper limit of normal); in-hospital left ventricular ejection fraction; reperfusion therapy use (among ST-segment-elevation myocardial infarction [STEMI] patients); revascularization (among non-STEMI patients); hospital region; and hospital teaching status. Using this model, we estimated each patient's probability of being enrolled in Part D conditioned on the patient's observed covariates. Each patient was then weighted by the inverse probability of treatment in a Cox proportional hazards regression model for outcomes, including Part D enrollment as the only fixed effect. Adjusted hazard ratios and 95% confidence intervals are reported for each outcome. We found good balance of covariates in this propensity model by assessing
Cramer phi for categorical variables and R 2 measure of association for continuous variables ( Figure I in the Data Supplement). We assessed medication adherence through 1 year among Part D enrollees. We included those patients enrolled for at least 90 days before discharge of the index AMI hospitalization (to account for legacy prescriptions that may have been filled before the index MI event), and who were alive without losing Part D eligibility through 1 year. Comparative 1-year adherence rates among nonenrollees could not be determined because prescription fill data were not available for nonenrollees. Adherence was defined as >80% days covered by prescription claims during the 1 year after discharge. 17 Adherence was assessed for each of 4 individual medication classes (P2Y 12 inhibitors, β-blockers, statins, and angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers) among those prescribed these medications at discharge. Adherence to aspirin was not assessed because it is usually obtained as an over-the-counter medication and would therefore not be captured by Medicare Part D claims.
A P value of <0.05 was considered statistically significant for all tests. All analyses were performed using SAS software (version 9.3; SAS Institute, Cary, NC).
Results
Of the 59 149 patients in this study, 29 264 patients (49.5%) were enrolled in Medicare Part D by hospital discharge, and 29 885 (50.5%) were not. The proportion of patients enrolled in Medicare Part D varied from month to month, but increased slightly over time (P for trend <0.0001; Figure 2 ). Among participating hospitals, the median rate of enrollment in Part D was 49.9%, but there was substantial variation in hospital participation rates ( Figure 3 enrollment rates of ≤38.2%, and top decile hospitals observed enrollment rates of ≥61.6% (Figure 3 ). There were no differences in teaching hospital status among enrollees versus nonenrollees (26.3% versus 26.2%; P=0.72). Table 1 shows baseline characteristics, in-hospital therapies, and discharge therapies of patients enrolled versus nonenrolled in Medicare Part D at the time of hospital discharge. Patients enrolled in Part D were more often women and of non-white race. Part D enrollees were more likely to have concomitant Medicaid coverage, whereas those without Part D were more likely to have additional private or military insurance. Compared with nonenrolled patients, enrollees were less likely to present with STEMI, and more frequently had previous cardiovascular disease (previous MI, heart failure, stroke, and peripheral arterial disease), as well as other comorbid conditions such as hypertension, dialysis, chronic lung disease, and diabetes mellitus ( Table 1 ). Enrollees were more likely to have a higher Charlson comorbidity index score, slightly higher ACTION Registry-GWTG mortality risk score 18 (an index of AMI severity), and previous hospitalization within the previous 12 months than nonenrollees.
Among STEMI patients, enrollees were more likely to receive thrombolytic therapy and less likely to receive primary percutaneous coronary intervention than nonenrolled patients. Among non-STEMI patients, Part D enrollees were more likely to be medically managed without percutaneous or surgical revascularization than nonenrolled patients (Table 1) . At hospital discharge, the use of evidence-based medications was similar among enrollees and nonenrollees ( Table 1) .
The unadjusted cumulative incidence rates of all 30-day and 1-year outcomes were higher among Part D enrollees than among nonenrollees ( Figure 4 ; Table 2 ). All-cause death at 30 days was more common among enrollees than among nonenrollees (4.0% versus 3.3%), but this difference was no longer statistically significant after multivariable adjustment (adjusted hazard ratio, 1.06 [95% confidence interval, 0.97-1.17]). The unadjusted risks of all-cause readmission and MACE within 30 days post discharge were also higher among Part D enrollees than among nonenrollees, but these differences were also attenuated after adjustment. Unadjusted event rates for 1-year outcomes were higher among Part D enrollees versus nonenrollees for mortality, readmissions, and MACE, but all of these associations were also attenuated after multivariable adjustment, with adjusted hazard ratios ranging between 1.05 and 1.09 ( Figure 4 ; Table 2 ). In the subset of patients enrolled in Part D for at least 90 days before discharge of index AMI hospitalization and who were alive without losing Part D eligibility through 1 year, medication adherence (defined as >80% days covered by prescription claims through 1 year) for individual medication classes ranged from 54.8% for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers to 63.6% for P2Y 12 inhibitors (Table 3 ) among patients prescribed each of these medications at discharge.
Discussion
This study is novel in linking a national clinical registry of acute MI with outpatient prescription filling data. Between 2007 and 2010, approximately half of all Medicare-insured patients hospitalized with AMI were enrolled in Medicare Part D by discharge. The rate of enrollment in Part D increased only slightly during the 4-year study period, and there was substantial variation in enrollment rates across US hospitals. Unadjusted rates of 30-day and 1-year outcomes (death, readmissions, and MACE) were higher among enrollees than among nonenrollees, but these differences were mostly attenuated after multivariable adjustment for patient and hospital characteristics. Prescription rates of evidence-based medications for AMI at hospital discharge were similar between Part D enrollees and nonenrollees. Among Part D enrollees, medication adherence rates at 1 year after discharge were only 55% to 64% for individual medication classes.
Few previous studies have reported rates of enrollment in Medicare Part D among eligible patients with cardiovascular disease. Eapen et al 19 found that only 60% of fee-for-service Medicare beneficiaries with heart failure were enrolled in Part D compared with a 50% enrollment rate among AMI patients in our study. Several factors contribute to these suboptimal Part D enrollment rates. There are >1700 stand-alone Medicare Part D prescription coverage plans available throughout the US, with an average 25 to 36 plans available per region. 20 Each of these plans differs on the benefit phases (deductible, generous coverage phase, coverage gap or doughnut hole, and catastrophic coverage phases), as well as the provision of the low-income subsidy. [19] [20] [21] The overwhelming number and complexity of Part D plans may either deter Part D eligible individuals from enrolling in Part D at all or may cause Part D enrollees to choose a plan that does not meet their needs. 22, 23 Other Medicare beneficiaries may not enroll in a Part D plan because they have alternate prescription coverage through an employer plan or through the Department of Veterans Affairs; these alternate prescription plans often provide superior coverage, require lower out-of-pocket expenses, and may be associated with better adherence rates than Part D plans. 24 We found no clinically meaningful association between Part D enrollment and 30-day and 1-year post-AMI outcomes after adjustment for patient characteristics, hospital factors, and census-derived indicators of socioeconomic ACE indicates angiotensin-converting enzyme; ACTION Registry-GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines; CABG, coronary artery bypass graft; eGFR, estimated glomerular filtration rate (as determined by the Cockroft-Gault formula); NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction.
*P values are based on Pearson χ 2 tests for all categorical row variables, and Wilcoxon rank-sum tests for all continuous/ordinal row variables.
†For each of these 5 variables of socioeconomic status, the values assigned to each patient are the values of surveyed people living in that patient's zip code according to US census data, as previously described. 16 ‡Patients could have >1 type of additional insurance. §Other insurance types include state-specific plans (non-Medicaid), Indian Health Service, or non-US insurance. ||To calculate the comorbidity index, 1 point is given for each of the following ≤1 year before index admission from Medicare Part A claims data: heart failure, cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, renal disease, hypertension, previous PCI, previous CABG, dementia, paraplegia/hemiplegia, cancer, and atrial fibrillation.
¶The ACTION Registry-GWTG mortality risk score estimates severity of illness of patients presenting with acute NSTEMI or STEMI. 18 #Excludes patients with contraindications to primary PCI or thrombolysis. **Excludes patients with contraindications to these medications. [25] [26] [27] These studies have shown that in patients hospitalized with AMI or unstable angina, rates of discontinuation of evidence-based cardiovascular medications were higher among Part D enrolled patients who experienced the coverage gap than those who did not. [25] [26] [27] However, these studies were inconclusive about the impact of the coverage gap on post-AMI clinical outcomes because of small sample sizes, low event rates, or short follow-up periods. 20, [25] [26] [27] There may be several reasons why despite adequate power our study did not demonstrate a convincing association between Part D enrollment and post-AMI clinical outcomes. First, Part D plans provide only partial prescription coverage with variable cost sharing structures and gaps in coverage. [19] [20] [21] In addition, ≈5 million Medicare beneficiaries may be eligible but do not apply for additional low-income subsidies to their Part D plan and therefore remain undercovered. 24 Second, many patients also spend their Part D coverage limits on medications that either do not improve outcomes or are even contraindicated for their chronic cardiovascular conditions (eg, use of relatively contraindicated medications in patients with heart failure, such as nonsteroidal anti-inflammatory drugs, steroids, and certain diabetes mellitus medications such as thiazoledinediones). 19 Most importantly, even adequate Part D coverage does not necessarily translate to improved adherence. In our study, adherence rates for Part D enrollees at 1 year ranged from 55% to 64% for individual drug classes (angiotensinconverting enzyme inhibitors or angiotensin receptor blockers, statins, P2Y 12 antagonists, and β-blockers). Stuart et al 21 found similar suboptimal rates of adherence after AMI among Part D enrollees, ranging from 40.4% to 61.6% (depending on drug class, Part D benefit phase, and low-income subsidy status). In another randomized controlled trial, 7 full prescription coverage (including elimination of copayments) for evidence-based medications after AMI improved adherence rates during longterm follow-up by only 4% to 6% when compared with usual prescription coverage. Accordingly, there was no difference 0.5 1 .0 1.5 in the primary outcome (first major vascular event or revascularization procedure) between full-versus usual-coverage groups. Reported adherence rates to evidence-based medications after acute coronary syndrome are low even in countries providing universal health coverage and low outpatient prescription costs, including in Canada (with 2-year adherence rate to statins of only 40.1%) 28 and in Denmark (with only 58% of post-AMI patients prescribed a β-blocker, of whom 78% and 64% were adherent at 1 and 3 years, respectively). 29 Taken together, these data illustrate that strategies focusing only on lowering cost barriers may not increase medication adherence rates enough to improve outcomes. A more comprehensive approach to addressing postdischarge medication adherence will likely be required, with adequate prescription coverage being 1 component of a multifaceted strategy. Our study has several limitations. First, although we adjusted for many patient and hospital factors, unmeasured confounders exist that preclude complete adjustment for factors that may impact the presence or lack of association between Part D enrollment and clinical outcomes. Second, despite linkage of 2 data sources, we did not have data on long-term medication adherence in patients who were not enrolled in Part D or on the rate of alternate prescription coverage (eg, through secondary private insurance, self-pay at discount pharmacies, or the Department of Veterans Affairs) among these patients. Third, neither the ACTION Registry-GWTG nor Medicare Part D claims collect data on individuals' socioeconomic status. However, we used patients' zip codes and US census data to include 5 indirect markers of socioeconomic status in our multivariable models as previously validated, 16 and this did not change our findings. Finally, our study included patients from >500 hospitals in the ACTION Registry-GWTG; however, these hospitals may have a greater commitment to quality improvement by virtue of their participation in a voluntary national quality improvement initiative. Our results may not be generalizable to all hospitals in the United States.
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Conclusions
Only half of eligible Medicare beneficiaries with AMI were enrolled in a Medicare Part D prescription plan at the time of discharge. Part D enrollment was not associated with better 30-day or 1-year outcomes after AMI. Among enrolled participants, long-term adherence to evidence-based medications was suboptimal. More research is needed to understand reasons for suboptimal Part D enrollment, and to delineate the components of the part D program that have the greatest influence on medication adherence. Medication adherence is defined as proportion of days of covered >80% within 1 year after discharge. ACE indicates angiotensin-converting enzyme.
